Merck & Co. is resubmitting the drug application for its combination cholesterol-lower drug MK-0653C, which was rejected by the Food and Drug Administration (FDA) last March due to insufficient data. The experimental medication combines a generic version of the cholesterol-lowering drug Lipitor, the top-selling medication of all time, with Merck’s cholesterol med Zetia. Lipitor and Zetia work in different ways to reduce high cholesterol and thus reduce the risk of heart attack and stroke. Lipitor, also known as atorvastatin, is a member of the statin drug family, which reduce the amount of cholesterol naturally produced in the liver. Zetia reduces the ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.